JAMA Network Home
Sign In
Research Letter

Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D

JAMA Network Open 10.1001/jamanetworkopen.2026.31556

August 17, 2026 at 11:00 AM EDT

Read the full article

This cross-sectional study investigates the cost and coverage of ustekinumab originator Stelara and biosimilar products in 2026 for Medicare Part D.

Corresponding Author: Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine, 2525 W End Ave, Ste 1209, Nashville, TN 37203 (s.dusetzina@vanderbilt.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.31556?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081726

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks